Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 1

Session XI: Presentation of Selected Abstracts: Colorectal Cancer

O-013: Impact of gender on the safety profile and outcome of chemotherapy plus bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies
Gemma Zucchelli, et al.

The conclusion from authors abstract:

The activity and efficacy of FOLFOXIRI/bevacizumab are independent of gender and age, with a relative increase in the risk of overall and CT-related AEs similar among age and gender subgroups. However, elderly and females pts are more likely to experience AEs regardless of the treatment arm. Considering the increased incidence of febrile neutropenia and diarrhea with FOLFOXIRI/bevacizumab, the use of G-CSF as primary prophylaxis or an initial dose reduction of irinotecan and 5-fluorouracil might be considered in this population. In females treated with FOLFOXIRI/bevacizumab the high incidence of nausea and vomiting may suggest the need for an intensification of the antiemetic prophylaxis. 



O-014: Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer (mCRC). A Danish randomized trial
Per Pfeiffer, et al.

The conclusion from authors abstract:

Conclusion
In patients with chemorefractory mCRC, FTD/TPI + bevacizumab demonstrated a significant and clinically relevant improvement in PFS and OS compared with FTD/TPI monotherapy, with a favorable safety profile.



O-015: Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results
Per Pfeiffer, et al.

The conclusion from authors abstract:

Cetuximab every two weeks with FOLFIRI or alternating FOLFIRI/FOLFOX were well tolerated with high RRs and long PFS and OS, however, Nordic 8 did not meet its primary endpoint and we recommend FOLFIRI + cetuximab every 2 weeks in patients with RAS and BRAF wild type mCRC.